México Tamaño, participación, tendencias y pronóstico del mercado de logística farmacéutica de cadena de frío por producto, servicio y región, 2026-2034

Size, share and outlook of the Mexican market for pharmaceutical cold chain logistics

The pharmaceutical cold chain logistics market in Mexico was valued at USD 192.5 million in 2025. Looking ahead, the market is projected to reach USD 465.3 million by 2034, exhibiting a compound annual growth rate (CAGR) of 10.30% during the period 2026–2034 . The market includes the growing demand for biopharmaceutical products and vaccines, which require strict temperature control. The rise in chronic diseases and the aging population are driving the need for temperature-sensitive medications. Technological advancements such as the Internet of Things (IoT), real-time tracking, and automation are improving supply chain reliability. Government initiatives and regulatory compliance (e.g., COFEPRIS) are also driving infrastructure improvements. Furthermore, Mexico's strategic location as a manufacturing and export hub to the US and Latin America fuels investment in cold chain logistics, increasing the market share of pharmaceutical cold chain logistics in Mexico.

Trends in the pharmaceutical cold chain logistics market in Mexico:

Growing demand for biopharmaceuticals and temperature-sensitive medicines

The Mexican pharmaceutical market is experiencing increased demand for biologics, vaccines, and other temperature-sensitive medications. These medications typically require strict temperature control between 2°C and 8°C during transport and storage, leading to investment in state-of-the-art cold chain infrastructure. Given Mexico's aging population and the rising incidence of chronic diseases, the demand for specialized medications continues to grow, compelling logistics providers to comply with stringent regulatory requirements (such as COFEPRIS standards) and minimize temperature deviations. Furthermore, pharmaceutical companies are collaborating with third-party logistics (3PL) providers specializing in the cold chain. Spending on real-time monitoring platforms, GPS tracking, and IoT-based cold storage systems is becoming increasingly common. This trend is further supported by Mexico's growing involvement in clinical trials and vaccine delivery throughout Latin America, which underscores the demand for efficient and scalable cold chain supply chains.

Expansion of infrastructure and regional logistics centers

Mexico is witnessing significant investments in cold storage facilities, transportation fleets, and regional distribution centers to support its growing pharmaceutical industry. Domestic and international logistics companies are expanding, particularly near border states like Nuevo León and Baja California, key transit points for U.S. exports. Monterrey, the capital of Nuevo León, attracted $69 billion in foreign direct investment in 2024, fueling infrastructure growth, including cold chain facilities. Mexico City and Guadalajara are also emerging as vital logistics hubs due to their strategic access to international airports and highways. Government initiatives promoting logistics modernization and partnerships with the private sector are driving the growth of the Mexican cold chain pharmaceutical logistics market. The development of regional centers decentralizes pharmaceutical distribution, ensuring faster and more reliable delivery, even in rural areas. These infrastructure improvements are crucial to meet growing domestic demand and support exports of temperature-sensitive products, such as vaccines, insulin, and biological products, which require strict temperature control during transit.

Technological integration and smart solutions for the cold chain

Technology is transforming cold chain logistics in Mexico's pharmaceutical industry. IoT, blockchain, and AI adoption are revolutionizing temperature-controlled supply chains by increasing visibility, traceability, and efficiency. Real-time monitoring of temperature, humidity, and location is now possible through IoT-enabled sensors, minimizing the risk of product spoilage. Blockchain provides immutable records that ensure product integrity and compliance with health regulations—crucial in an industry where patient safety is paramount. Furthermore, AI-powered predictive analytics are being applied to optimize route planning and anticipate disruptions, reducing costs and improving delivery accuracy. These technologies are also enhancing automation in cold storage and improving last-mile delivery performance. With Mexico further solidifying its role as a pharmaceutical manufacturing hub and export base, particularly to the US and Latin America, the demand for digitally integrated, end-to-end cold chain solutions is expected to grow significantly.

Segmentation of the pharmaceutical cold chain logistics market in Mexico:

The IMARC Group offers an analysis of key trends in each market segment, along with national and regional forecasts for 2026-2034. Our report has categorized the market based on product and service.

Product Perspectives:

• Vaccines
• Biopharmaceutical products
• Materials for clinical trials

The report offers a detailed breakdown and analysis of the market by product. This includes vaccines, biopharmaceuticals, and clinical trial materials.

Service prospects:

• Storage and VAS
• Transport

The report also provides a detailed breakdown and analysis of the market by service. This includes storage and VAS, and transportation.

Regional perspectives:

• Northern Mexico
• Central Mexico
• Southern Mexico
• Others

The report also provided a comprehensive analysis of key regional markets, including northern, central, and southern Mexico, among others.

Competitive landscape:

The market research report also provides a comprehensive analysis of the competitive landscape. This includes competitive analysis such as market structure, key player positioning, leading winning strategies, a competitive dashboard, and a company assessment quadrant. Detailed profiles of the top companies are also provided.

News from the Pharmaceutical Cold Chain Logistics Market in Mexico:

• En febrero de 2025,UPS Healthcare lanzó nuevas instalaciones de cross-dock de cadena de frío en la Ciudad de México, Milán y Frankfurt para apoyar los envíos farmacéuticos sensibles a la temperatura. Certificados por la norma CEIV Pharma de IATA, estos centros garantizan un transporte seguro desde condiciones ambientales a congeladas. Las instalaciones de México se extienden a lo largo de 10.700 m², mejorando la logística regional. Estas ubicaciones estratégicas permiten entregas más rápidas, apoyando la creciente demanda de productos sanitarios con temperatura controlada, y fortaleciendo la red global de UPS para soluciones fiables e integrales de la cadena de frío.
• En enero de 2025,Emergent Cold LatAm completó la adquisición de un almacén frigorífico de 45.000 m² en Duque de Caxias, Río de Janeiro, ampliando su red en el centro de distribución clave de Brasil. Esta adquisición apoya los planes de expansión acelerada de la empresa, con cinco grandes proyectos previstos en todo Brasil. Emergent Cold LatAm tiene como objetivo fortalecer sus capacidades logísticas de la cadena de frío y servir mejor a los clientes en toda América Latina.

Cobertura del mercado de logística farmacéutica de cadena de frío en México:

Preguntas clave respondidas en este informe:

• ¿Cómo se ha comportado hasta ahora el mercado mexicano de logística farmacéutica de cadena de frío y cómo se comportará en los próximos años?
• ¿Cuál es la distribución del mercado mexicano de logística farmacéutica de cadena de frío por productos?
• ¿Cuál es el desglose del mercado mexicano de logística farmacéutica de cadena de frío en función del servicio?
• ¿Cuál es el desglose del mercado mexicano de logística farmacéutica de cadena de frío por regiones?
• ¿Cuáles son las diferentes etapas de la cadena de valor del mercado de logística farmacéutica de cadena de frío en México?
• ¿Cuáles son los principales factores impulsores y los retos del mercado de la logística farmacéutica de cadena de frío en México?
• ¿Cuál es la estructura del mercado mexicano de logística farmacéutica de cadena de frío y quiénes son sus principales actores?
• What is the level of competition in the Mexican market for pharmaceutical cold chain logistics?

Main benefits for stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and market dynamics of the pharmaceutical cold chain logistics market in Mexico from 2020-2034.
• The research report provides the latest information on market drivers, challenges, and opportunities in the pharmaceutical cold chain logistics market in Mexico.
• Porter's Five Forces analysis helps stakeholders assess the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the pharmaceutical cold chain logistics industry in Mexico and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of the major market players.